RAPP · Rapport Therapeutics, Inc.

The thesis

Rapport Therapeutics' drug RAP-219 beat placebo in acute bipolar mania by 3.1 points on the Young Mania Rating Scale (YMRS), which is below the 4-point bar management called clinically meaningful on 23 September 2026. The company then priced new shares at $21.00 on 28 October 2026, and the shares closed at $22.50 that day (adjusted daily close), 57.1% below the $52.50 52-week high. The 5 November 2026 (est.) third-quarter report shows how much cash the financing added and what the next trials cost.

The previous note named two conditions that would end the case: a bipolar-mania result at or under the 4-point bar, and a close below $29. Both have happened. The company's 20 October 2026 release calls the result positive, with a p-value of 0.045 in 253 adults. The narrative is maturing: the data are out, analysts have reset targets, and attention has moved to dilution and safety since the 27 October 2026 offering announcement.

Bullish and bearish views on Rapport Therapeutics, Inc.

The bull case on Rapport Therapeutics, Inc. (RAPP), in brief: The primary endpoint was met. The bear case: The result missed management's own bar.

Bull case

• The primary endpoint was met. Rapport reported on 20 October 2026 a 3.1-point placebo-adjusted YMRS improvement at Week 3 (p=0.045) in 253 adults with bipolar I disorder. A secondary mania severity measure also improved by 0.4 points (p=0.024).
• Several brokers raised targets after the data. Raymond James raised its target to $86 from $75 on 20 October 2026, and Jones Trading went to $82 on 21 October 2026. Guggenheim moved to $70 on 21 October 2026, and Citizens went to $91 from $80, per press reports. All sit far above the $22.50 close.
• Serious safety events were absent. The company reported no severe treatment-emergent or serious adverse events over the treatment period. The company says the results support Phase 3, with trials expected in the second half of 2027.
• A director bought shares. Company news on 23 October 2026 reported a significant director share purchase, four days before the offering was announced.

Bear case

• The result missed management's own bar. The 3.1-point gap is 0.9 points under the 4-point threshold set on 23 September 2026. Raymond James noted the shortfall in its target note, per press reports.
• Tolerability looks weaker than placebo. Discontinuations due to adverse events were 3.2% on RAP-219 versus 0.8% on placebo, per the company's release. TIKR reported agitation at 16.7% versus 9.4%. Wells Fargo cut its target to $50 on 21 October 2026 and flagged agitation-related side effects and discontinuations.
• The company issued shares at a lower price. Rapport announced offerings of $200M of stock and $150M of convertible senior notes on 27 October 2026. Headlines on 28 October 2026 reported about $175M of stock at $21.00 plus pre-funded warrants for about $25M, and the shares fell about 20% after hours. The final size of the convertible notes was not in the pricing headlines.
• Momentum remains weak. The shares have fallen 45.1% over three months, and the 14-day relative strength index is 33.6. The close was $25.33 on 26 October 2026 (SEC prospectus supplement) and $22.50 on 28 October 2026.
• Phase 3 is far away. The company guides Phase 3 starts to the second half of 2027, so no pivotal data will arrive within this tracking window.

Price setup

The shares closed at $29.57 on 15 October 2026, $25.33 on 26 October 2026 and $22.50 on 28 October 2026 (adjusted daily closes and the SEC prospectus). The $29 level from the previous note and the $42.27 June–July breakout level are both well above the close. The $21.00 offering price sits 1.50 below the close. Underwriters and investors who bought at $21.00 are the nearest visible reference group.

Crowding evidence points to a position being unwound and new supply arriving. Rapport issued stock and pre-funded warrants on 27 October to 28 October 2026, an earnings date is about a week away, and insiders had sold near $48 in the quarter before (Form 4 filings, MarketBeat, 23 September 2026). Trading volume has been thin in past sessions, so single-day moves of high single digits are common.

Catalysts, next 30 days

• Q4 2026 (company guided): open-label extension data in focal onset seizures. The company guides this release; it adds safety and durability evidence alongside the enrolling Phase 3 FOCUS trials.
• Q1 2027 (reported by one outlet): FDA meeting on bipolar mania. It would set the Phase 3 design for the indication whose Phase 2 result fell under the 4-point bar.

Elapsed catalysts

• ~5 November 2026 (est.): third-quarter 2026 report. It shows the cash balance after the offering and whether quarterly R&D holds near the $51.4M reported for the second quarter. (passed 1d ago)

What would change the view

The case breaks on a daily close below $20.00, under the $21.00 offering price, or on a disclosed clinical hold or serious safety event in any RAP-219 program. A single molecule drives all four programs, so one safety finding reaches every indication.

A stronger case would need evidence that tolerability is manageable, such as lower discontinuations in the focal seizure extension data, or an FDA meeting outcome that accepts a smaller effect size as the basis for Phase 3. Neither has been reported.

What it trades with

The shares move with small and mid-sized clinical-stage biotech companies and with the sector's appetite for financing. Moves in the Nasdaq Biotechnology Index and neuropsychiatry peers' trial news are the nearest outside drivers.